Immunotherapy Treating GI Cancer

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT03614650
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
1 Year - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • engineered immune cells — BIOLOGICAL
    Engineered immune effector cells (EIE)

Study Details

The primary objectives are to evaluate the safety and efficacy of infusion of autologous gastro-intestinal (GI) cancer antigen-specific engineered immune effector cells (EIE).

Key Dates

First listed
Aug 3, 2018
Start date
Jun 1, 2027
Status verified
Aug 2026
Primary completion
Jun 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: EIE cells to treat cancer
    EIE cells to treat cancer

Primary Outcome Measure

percentage of adverse effects after EIE cell injection [ Time Frame: up to one month ]

Central Contacts

Related Studies